Epizyme Inc. [EPZM] is -30.69% lower this YTD. Is it still time to buy?



Epizyme Inc. [NASDAQ: EPZM] loss -6.83% or -1.25 points to close at $17.05 with a heavy trading volume of 1269579 shares. It opened the trading session at $17.49, the shares rose to $18.25 and dropped to $17.03, the range by which the price of stock traded the whole day. The daily chart for EPZM points out that the company has recorded -9.36% loss over the past six months. However, it is still -75.23% lower than its most recent low trading price.

If we look at the average trading volume of 881.61K shares, EPZM reached to a volume of 1269579 in the most recent trading day, which is why market watchdogs consider the stock to be active.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Here is what top equities market gurus are saying about Epizyme Inc. [EPZM]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EPZM shares is $29.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EPZM stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Oppenheimer have made an estimate for Epizyme Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on April 01, 2020. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on March 04, 2020, representing the official price target for Epizyme Inc. stock. Previously, the target price had yet another raise from $25 to $36, while H.C. Wainwright kept a Buy rating on EPZM stock.

The Average True Range (ATR) for Epizyme Inc. is set at 1.08, with the Price to Sales ratio for EPZM stock in the period of the last 12 months amounting to 99.20. The Price to Book ratio for the last quarter was 5.59, with the Price to Cash per share for the same quarter was set at 3.74.

Trading performance analysis for EPZM stock

Epizyme Inc. [EPZM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.35. With this latest performance, EPZM shares dropped by -2.90% in over the last four-week period, additionally sinking by -9.36% over the last 6 months – not to mention a rise of 40.91% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EPZM stock in for the last two-week period is set at 43.76, with the RSI for the last a single of trading hit 41.86, and the three-weeks RSI is set at 46.73 for Epizyme Inc. [EPZM]. The present Moving Average for the last 50 days of trading for this stock 17.35, while it was recorded at 17.54 for the last single week of trading, and 17.18 for the last 200 days.

Epizyme Inc. [EPZM]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Epizyme Inc. [EPZM] shares currently have an operating margin of -744.29. Epizyme Inc.’s Net Margin is presently recorded at -715.53.

Return on Total Capital for EPZM is now -56.92, given the latest momentum, and Return on Invested Capital for the company is -54.99. Return on Equity for this stock declined to -60.37, with Return on Assets sitting at -48.25. When it comes to the capital structure of this company, Epizyme Inc. [EPZM] has a Total Debt to Total Equity ratio set at 17.59. Additionally, EPZM Total Debt to Total Capital is recorded at 14.96, with Total Debt to Total Assets ending up at 13.54. Long-Term Debt to Equity for the company is recorded at 18.80, with the Long-Term Debt to Total Capital now at 14.18.

Reflecting on the efficiency of the workforce at the company, Epizyme Inc. [EPZM] managed to generate an average of -$838,892 per employee. Receivables Turnover for the company is 1.96 with a Total Asset Turnover recorded at a value of 0.07.Epizyme Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 14.70 and a Current Ratio set at 14.80.

Epizyme Inc. [EPZM]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Epizyme Inc. posted -0.53/share EPS, while the average EPS was predicted by analysts to be reported at -0.53/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EPZM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Epizyme Inc. go to 38.00%.

An analysis of insider ownership at Epizyme Inc. [EPZM]

There are presently around $1,690 million, or 95.90% of EPZM stock, in the hands of institutional investors. The top three institutional holders of EPZM stocks are: PRIMECAP MANAGEMENT CO/CA/ with ownership of 13,564,581, which is approximately -0.692% of the company’s market cap and around 0.50% of the total institutional ownership; RP MANAGEMENT, LLC, holding 9,166,667 shares of the stock with an approximate value of $167.75 million in EPZM stocks shares; and REDMILE GROUP, LLC, currently with $160.46 million in EPZM stock with ownership of nearly 0.257% of the company’s market capitalization.

Positions in Epizyme Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 82 institutional holders increased their position in Epizyme Inc. [NASDAQ:EPZM] by around 7,184,173 shares. Additionally, 70 investors decreased positions by around 6,409,801 shares, while 13 investors held positions by with 78,729,030 shares. The mentioned changes placed institutional holdings at 92,323,004 shares, according to the latest SEC report filing. EPZM stock had 31 new institutional investments in for a total of 1,274,651 shares, while 22 institutional investors sold positions of 1,677,547 shares during the same period.



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam